63 patients with chronic hepatitis B with moderate hepatitis activity were investigated. Basis therapy + placebo were prescribed for 30 patients and basis therapy + amixin IC were prescribed for 33 patients. It was found that using of amixin IC has a positive influence on processes of interferonogenesis, clinical manifestations of the disease (shortening of bilirubinemia’s time, decrease of cytolithic component), promoted further elimination of hepatitis B virus from patient’s organism.
